Alternative gel Papaver somniferum (poppy) and Cannabis sativa (marihuana), as treatment of rheumatoid arthritis

Ana R Ramírez Jiménez; Adrián Ruiz Olvera; Virginia Melo Ruiz; Maritza García

2011, Number 1

<< Back Next >>

Enf Neurol (Mex) 2011; 10 (1)

**Alternative gel Papaver somniferum (poppy) and Cannabis sativa (marihuana), as treatment of rheumatoid arthritis**

Ramírez JAR, Ruiz OA, Melo RV, García M

Full text

How to cite this article

Language: Spanish
References: 23
Page: 16-20
PDF size: 248.77 Kb.

ABSTRACT

The development of this pharmaceutical product is a pharmaceutical formulation between gel and fluid emulsion, which used two natural active ingredients considered psychotropic or narcotic, alcoholic extract of poppy (Papaver somniferum) and alcoholic extract of marijuana (Cannabis sativa), they have known biological activity within the body. They are excellent analgesics for terminal cancer patients but also have antiemetic properties, stimulating appetite, soothing eye, bronchitis, anxiety. It is known that for a sustained release of active principle is very useful the use of liposomes; for this reason, liposomes of alcoholic extract of poppy considering that this plant has better analgesic properties of marijuana for which the latter extract includes 40% of the formulation. The results obtained after processing of the product were favorable in relation to quality control. The work is a gel for topical use, this pharmaceutical composition is a reservoir of active ingredients in a transdermal delivery system, has a remarkable stability and optimal orgaleptics characteristics.

REFERENCES

Alfonso R. Gennaro Remington Farmacia. 20a Edición Ed. Panamericana. 2000; II: 1716-1718.
Ball E. Liposomas en dermatología. Derm Venez 1995; 33: 15-23.
Escuela Andaluza de Salud Pública Glucosamina en Artrosis: ¿previene la progresión de la enfermedad? Boletín Terapéutico Andaluz (BTA) 2002; 18(5): 17-18/1.
Escuela Andaluza de Salud Pública. Tratamiento de la artritis reumatoide en adultos. Boletín Terapéutico Andaluz (BTA) 2003; 19 (4): 13-16.
Flores J. Farmacología humana. 9a Edición Editorial McGraw-Hill Interamericana.
Fontelles M. Fármacos y fisiopatología.
Frezard. Liposomes: from biophysics to the design of peptide vaccines. Braz J Med Biol Res 1999; 32: 181-189.
Gregodiaris G. Liposome Technology: Interactions of liposomes with the biological milieu. Healthcare 2007.
Goodman y Gilman. Las bases farmacológicas de la terapéutica. 10a Edición. México. D.F., México. 2002.
Isselbacher KJ, Braunwald BE, Harrison WJ. Principios de medicina interna. 13va Ed. Madrid: Interamericana McGraw-Hill 1994: I.
Kemp S, Holloword T, Joanne H. Sensory evaluation. Ed John Wiley & Sons, England 2009.
Lista amarilla de estupefacientes. www.incb.org/pdf/s/list/amarilla.pdf. Consulta de marzo de 2010.
Naveros CB. Sistemas de transporte y libración de fármacos de aplicación tópica: liposomas multilaminares portadores de acetonido de triamicinolona. Universidad de Granda, 2003.
New, “Liposomes-a practical approach,” edited by BDHD Rickwood, Vol. 58 (IRL Press at Oxford University Press, 1994).
O’Brien T, Welsh J, Dunn FG. ABC of palliative care: Non-malignant conditions. BMJ 1998; 316: 286-289.
O’Brien T, Kelly M, Saunders CM. Motor neurone disease: a hospice perspective. BMJ 1992; 304: 471-473.
Schäfer M, Carter L, Stein C. Interleukin 1 b and corticotrofin-releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci USA 1994; 91: 4219-4223.
Wilson JI, Carmody JJ, Walker JS. The importance of the hypothalamo-hypophyseal-adrenal axis to the anti-inflammatory actions of the k-opioid agonist PNU-50,488H in rats with adjuvant arthritis. J Pharmacol Exp Ther 2000; 294 (3): 1131-1136.